Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

1.7K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.7K
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

2.1K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
2.1K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

967
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
967
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

410
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
410
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

741
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
741

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Correct neonatal free thyroxine reference intervals are crucial to detect central congenital hypothyroidism.

European journal of endocrinology·2026
Same author

Autoantibody-Positive versus Autoantibody-Negative Type 1 Diabetes in Children: Clinical and Biochemical Characteristics.

Hormone research in paediatrics·2026
Same author

Multi-omics investigation of thyroid development and dysfunction in down syndrome.

Human molecular genetics·2026
Same author

HRQoL in Adolescents with Idiopathic Isolated GHD: rhGH (Dis)continuation in Mid-Puberty.

Endocrine connections·2026
Same author

Response to Letter to the Editor on "Feminine figures: body image and physical characteristics in trans women after puberty suppression and subsequent estradiol therapy".

The journal of sexual medicine·2026
Same author

International Consensus on the Requirements for Definitions of Complete Remission and Recurrence of Differentiated Thyroid Cancer: a Delphi Study (ICON-DTC).

European journal of endocrinology·2025

相关实验视频

Updated: May 2, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K

在患有家族性高胆固醇血症的儿童中,他类药物治疗的有效性和安全性:一项随机,双盲,安慰剂对照试验,使用simvastatin.

Saskia de Jongh1, Leiv Ose, Tamás Szamosi

  • 1Department of Vascular Medicine, Emma Children's Hospital, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands. s.dejongh@amc.uva.nl

Circulation
|October 23, 2002
PubMed
概括

西姆瓦斯塔丁有效降低LDL胆固醇在异性家族高胆固醇血症 (heFH) 的儿童,而不会影响成长或青春期. 这项研究证实了simvastatin作为儿童heFH患者的安全和有效的治疗选择.

更多相关视频

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

7.5K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K

相关实验视频

Last Updated: May 2, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

14.8K
A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes
10:56

A Familial Hypercholesterolemia Human Liver Chimeric Mouse Model Using Induced Pluripotent Stem Cell-derived Hepatocytes

Published on: September 15, 2018

7.5K
LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring
08:45

LDL Cholesterol Uptake Assay Using Live Cell Imaging Analysis with Cell Health Monitoring

Published on: November 17, 2018

13.2K

科学领域:

  • 儿童心脏病学 儿童心脏病学
  • 临床药理学 临床药理学
  • 遗传学和遗传性疾病

背景情况:

  • 异构性家族性高胆固醇血症 (heFH) 是一种导致高LDL胆固醇水平的遗传疾病.
  • 早期干预对于预防heFH儿童心血管疾病至关重要.
  • 评估儿童群体降脂疗法的疗效和安全性至关重要.

研究的目的:

  • 评估simvastatin在患有heFH的儿童中降低LDL胆固醇的疗效.
  • 在这个队列中评估simvastatin的整体安全性和耐受性.
  • 为了确定simvastatin对生长和青春期发育的影响.

主要方法:

  • 一个多中心,随机,双盲,安慰剂控制的研究.
  • 173名患有heFH的儿童随机分配给接受simvastatin (高达40毫克/天) 或安慰剂,持续48周.
  • 监测了安全性,耐受性,脂质水平和荷尔蒙/生长参数.

主要成果:

  • 西姆瓦斯塔丁显著降低了LDL胆固醇 (-41%),总胆固醇 (-31%),阿波利波蛋白B (-34%),VLDL胆固醇 (-21%),以及甘油三 (-9%).
  • 高密度高脂胆固醇和阿波利波蛋白A-I显示非显著的增加.
  • 没有观察到对生长,青春期发育或荷尔蒙水平 (除了轻微的脱乙硫酸变化) 的显著不良影响.

结论:

  • 辛巴斯塔丁是一种耐受性良好且有效的治疗方法,用于降低患有heFH的儿童的脂质水平.
  • 该研究没有发现对生长和青春期发育有不良影响的证据.
  • 高达40毫克的simvastatin是儿科heFH的安全治疗选择.